Idiopathic pulmonary fibrosis (IPF), the most common form of idiopathic interstitial
pneumonia, is a progressive, irreversible, and typically lethal disease characterized by an …

The approval of the first small interfering RNA (siRNA) drug Patisiran by FDA in 2018 marks
a new era of RNA interference (RNAi) therapeutics. MicroRNAs (miRNA), an important post …

Genome-wide association studies have identified thousands of noncoding variants
associated with human traits and diseases. However, the functional interpretation of these …

The extracellular matrix (ECM) provides structural support and imparts a wide variety of
environmental cues to cells. In the past decade, a growing body of work revealed that the …

Abstract Fine particulate matters (PM2. 5) increased the risk of pulmonary fibrosis. However,
the regulatory mechanisms of lung epithelium in pulmonary fibrosis remained elusive. Here …

Alternative polyadenylation (APA) creates distinct transcripts from the same gene by
cleaving the pre-mRNA at poly (A) sites that can lie within the 3′ untranslated region (3 …

A crucial feature of gene expression involves RNA processing to produce 3′ ends through
a process termed 3′ end cleavage and polyadenylation (CPA). This ensures the nascent …

Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous and fatal disease. However,
IPF treatment has been limited by the low drug delivery efficiency to lungs and dysfunctional …

ABSTRACT The Cre/Lox system is a powerful tool in the biologist's toolbox, allowing loss‐of‐
function and gain‐of‐function studies, as well as lineage tracing, through gene …

Development and homeostasis rely upon concerted regulatory pathways to establish the
specialized cell types needed for tissue function. Once a cell type is specified, the processes …